980P - Advanced acinic cell carcinoma harbors kinase rearrangements including BRAF kinase domain duplications

Date 09 October 2016
Event ESMO 2016 Congress
Session Poster display
Topics Head and Neck Cancers
Presenter Siraj Ali
Citation Annals of Oncology (2016) 27 (6): 328-350. 10.1093/annonc/mdw376
Authors S.M. Ali1, K. Fedorchak2, A.B. Schrock3, J. Johnson4, K. Gowen2, J.A. Elvin5, J. Vergilio5, S.J. Klempner6, R. Mehra7, A. Ho8, D. Pavlick2, J. Suh5, R. Bordoni9, D.H. Jung10, P. Stephens2, C.H. Chung11, J.S. Ross12, V. Miller13
  • 1Research And Development, Foundation Medicine, Inc, 02141 - Cambridge/US
  • 2Research And Development, Foundation Medicine, Inc, Cambridge/US
  • 3Clinical Development, Foundation Medicine, Inc., Cambridge/US
  • 4Medical Oncology, Kimmel Cancer Center-Thomas Jefferson University, Philadelphia/US
  • 5Pathology, Foundation Medicine, Inc., 02141 - Cambridge/US
  • 6Medical Oncology, The Angeles Clinic and Research Institute, 90025 - Los Angeles/US
  • 7Oncology, Fox Chase Cancer Center, Philadelphia/US
  • 8Medical Oncology, Memorial Sloan Kettering Cancer Center, New York/US
  • 9Medical Oncology, Georgia Cancer Specialists, marietta/US
  • 10Otolarynology, Mass Eye and Ear Infirmary, Boston/US
  • 11Medical Oncology, H. Lee Moffitt Cancer Center University of South Florida, Tampa/US
  • 12Pathology, Albany Medical Center, 12208 - Albany/US
  • 13Clinical Development, Foundation Medicine, Inc., 02141 - Cambridge/US



A subset of patients with acinic cell carcinoma (AcCC), a typically indolent tumor arising from the exocrine cells of salivary glands, will experience substantial morbidity and mortality from recurrent and metastatic disease. No consensus guidelines exist for management of advanced AcCC.


72 advanced AcCC cases were assayed with hybrid-capture based comprehensive genomic profiling (CGP) in the course of clinical care to identify genomic alterations (GA) suggesting benefit from targeted therapy.


61 (85%) of AcCC had at least one GA (mean 2.1 GA per case), and clinically relevant genomic alterations (CRGA) were identified in 27 (38%) AcCC cases. The genes most commonly altered were CDKN2A (60%), PTEN (8%), and TP53 (7%). Other genes altered at 4% or less included FBXW7, ATM1, NF1 and BRAF. GAs affecting the PI3K/AKT/mTOR pathway (PTEN, PIK3CA, FBXW7) were present in 15% of cases, and no other signaling pathways were repeatedly perturbed. Of three BRAF altered cases (4%), one harbored a V600E mutation and two harbored BRAF kinase domain duplications (KDD), with one of the latter patients having a >6 month dramatic response to the promiscuous RAF inhibitor regorafenib. Three cases (4%), all of parotid origin, harbored ETV6-NTRK3 fusions. One patient responded to entrectinib (Drillon et al 2016), and another has been enrolled in a trial for investigational inhibitor.


Advanced AcCC is the first tumor type to be identified as harboring recurrent BRAF KDD, which is associated with clinical benefit from regorafenib. Moreover, detection of ETV6-NTRK3 in these cases is widely interpreted as a diagnostic of mammary analogue secretory carcinoma (MASC) with such patients predicted to benefit from NTRK inhibitors. Further investigations including RNA-sequencing are underway to define additional targetable oncogenic drivers in advanced AcCC cases not harboring the above alterations.

Clinical trial identification

Legal entity responsible for the study

Siraj Ali




S.M. Ali, K. Fedorchak, A.B. Schrock, K. Gowen, J.A. Elvin, J-A. Vergilio, D. Pavlick, J. Suh, P. Stephens, J.S. Ross, V. Miller: Employee of and equity interest in foundation medicine inc. S.J. Klempner: Speakers bureau for foundation medicine inc. All other authors have declared no conflicts of interest.